Miricorilant

Phase 2Small molecule

Miricorilant is one of 51 small molecule programs targeting Non-alcoholic Steatohepatitis (NASH). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic Steatohepatitis (NASH)Active, not recruiting

Adult SubjectActive, not recruiting

HepatitisActive, not recruiting

Non-Alcoholic Steatohepatitis (NASH)Phase 1

Active, not recruiting

Adult SubjectPhase 1

Active, not recruiting

HepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Hepatitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

2 2

Sovaldi

Gilead

Approved

1 3

Viread

Tyzeka

Glucophage

3 6

Singulair

OOrganon and Co

Approved

1 7

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 8

Epivir

GGlaxo Dba Glaxosmithkline

Approved

—9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

8 10

Cellcept

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis3 trials

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Terminated·CCorcept Therapeutics·Phase 2·NCT03823703·12 enrolled

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Active, not recruiting·CCorcept Therapeutics·Phase 2·NCT06108219·175 enrolled

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Completed·CCorcept Therapeutics·Phase 1·NCT05117489·70 enrolled

Tics1 trial

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Completed·CCorcept Therapeutics·Phase 1·NCT05712265·26 enrolled

Hepatic Impairment1 trial

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Completed·CCorcept Therapeutics·Phase 1·NCT05553470·19 enrolled

Adult Subject1 trial

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

Active, not recruiting·CCorcept Therapeutics·Phase 1·NCT07240116·18 enrolled

Alcoholism1 trial

Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo

Completed·TThe Scripps Research Institute·Phase 2·NCT04466215·50 enrolled

3 more indications

ART1 trial

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Completed·CCorcept Therapeutics·Phase 1·NCT04672499·36 enrolled

Bipolar Disorder1 trial

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

Completed·CCorcept Therapeutics·Phase 2·NCT03818256·71 enrolled

Non-alcoholic Steatohepatitis (NASH)1 trial

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Active, not recruiting·CCorcept Therapeutics·Phase 1·NCT06947304·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Miricorilant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Miricorilant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Miricorilant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corcept Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCorcept Therapeutics

Miricorilant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis3 trials

Tics1 trial

Hepatic Impairment1 trial

Adult Subject1 trial

Alcoholism1 trial

ART1 trial

Bipolar Disorder1 trial

Non-alcoholic Steatohepatitis (NASH)1 trial

References

Drug Info

Quick Facts

Related News